Hedi Schelleman

1.5k total citations
30 papers, 1.1k citations indexed

About

Hedi Schelleman is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, Hedi Schelleman has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 12 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Pharmacology. Recurrent topics in Hedi Schelleman's work include Hormonal Regulation and Hypertension (12 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Blood Pressure and Hypertension Studies (8 papers). Hedi Schelleman is often cited by papers focused on Hormonal Regulation and Hypertension (12 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Blood Pressure and Hypertension Studies (8 papers). Hedi Schelleman collaborates with scholars based in United States, Netherlands and Canada. Hedi Schelleman's co-authors include Sean Hennessy, Warren B. Bilker, Stephen E. Kimmel, Colleen Brensinger, Anthonius de Boer, Olaf H. Klungel, Mark J. Cziraky, James P. Guevara, Gregory W. Daniel and Fei Wan and has published in prestigious journals such as PLoS ONE, American Journal of Psychiatry and PEDIATRICS.

In The Last Decade

Hedi Schelleman

30 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hedi Schelleman United States 19 406 359 271 225 164 30 1.1k
Stephen D. Wise Singapore 16 163 0.4× 244 0.7× 228 0.8× 142 0.6× 207 1.3× 29 985
Menger Chung United States 17 119 0.3× 173 0.5× 114 0.4× 194 0.9× 262 1.6× 29 891
Wayne T. Nicholson United States 24 596 1.5× 432 1.2× 119 0.4× 54 0.2× 125 0.8× 78 1.8k
Marine L. Andersson Sweden 16 182 0.4× 242 0.7× 66 0.2× 66 0.3× 75 0.5× 32 787
Rebecca N Gray United States 14 228 0.6× 71 0.2× 93 0.3× 229 1.0× 73 0.4× 22 847
Д. А. Сычев Russia 13 215 0.5× 249 0.7× 53 0.2× 101 0.4× 125 0.8× 283 804
LE Ramsay United Kingdom 16 579 1.4× 172 0.5× 287 1.1× 40 0.2× 127 0.8× 53 1.2k
A Breckenridge United Kingdom 17 242 0.6× 326 0.9× 138 0.5× 64 0.3× 92 0.6× 57 1.1k
Lindon Wing Australia 19 499 1.2× 128 0.4× 172 0.6× 33 0.1× 101 0.6× 55 1.1k
M. Kristensen Denmark 16 142 0.3× 147 0.4× 114 0.4× 244 1.1× 282 1.7× 26 1.3k

Countries citing papers authored by Hedi Schelleman

Since Specialization
Citations

This map shows the geographic impact of Hedi Schelleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hedi Schelleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hedi Schelleman more than expected).

Fields of papers citing papers by Hedi Schelleman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hedi Schelleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hedi Schelleman. The network helps show where Hedi Schelleman may publish in the future.

Co-authorship network of co-authors of Hedi Schelleman

This figure shows the co-authorship network connecting the top 25 collaborators of Hedi Schelleman. A scholar is included among the top collaborators of Hedi Schelleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hedi Schelleman. Hedi Schelleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mölken, Maureen Rutten‐van, et al.. (2025). Preparing for the EU HTA Regulation: Insights from the Dutch Perspective. Journal of Market Access & Health Policy. 13(3). 35–35. 1 indexed citations
2.
Schelleman, Hedi, et al.. (2015). Why we should have more collaboration on HTA in Europe: the example of sofosbuvir. Journal of Pharmaceutical Policy and Practice. 8(S1). 2 indexed citations
3.
Schelleman, Hedi, Warren B. Bilker, Stephen E. Kimmel, et al.. (2013). Amphetamines, Atomoxetine and the Risk of Serious Cardiovascular Events in Adults. PLoS ONE. 8(1). e52991–e52991. 24 indexed citations
4.
Kimmel, Stephen E., Hedi Schelleman, Jesse A. Berlin, et al.. (2011). The effect of selective serotonin re‐uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. British Journal of Clinical Pharmacology. 72(3). 514–517. 39 indexed citations
5.
Schelleman, Hedi, Warren B. Bilker, Brian L. Strom, et al.. (2011). Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents. PEDIATRICS. 127(6). 1102–1110. 104 indexed citations
6.
Schelleman, Hedi, Warren B. Bilker, Colleen Brensinger, et al.. (2010). Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk. The American Journal of Medicine. 123(2). 151–157. 60 indexed citations
7.
Schelleman, Hedi, et al.. (2010). Anti-Infectives and the Risk of Severe Hypoglycemia in Users of Glipizide or Glyburide. Clinical Pharmacology & Therapeutics. 88(2). 214–222. 65 indexed citations
8.
Hennessy, Sean, Hedi Schelleman, Gregory W. Daniel, et al.. (2010). Cardiovascular safety of ADHD medications: rationale for and design of an investigator‐initiated observational study. Pharmacoepidemiology and Drug Safety. 19(9). 934–941. 10 indexed citations
9.
Schelleman, Hedi, Nita A. Limdi, & Stephen E. Kimmel. (2008). Ethnic Differences in Warfarin Maintenance dose Requirement and its Relationship with Genetics. Pharmacogenomics. 9(9). 1331–1346. 44 indexed citations
10.
Schelleman, Hedi, Olaf H. Klungel, Jacqueline C.M. Witteman, et al.. (2008). Interaction between polymorphisms in the renin–angiotensin–system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal. 8(6). 400–407. 14 indexed citations
11.
Schelleman, Hedi, Jie Chen, Zhen Chen, et al.. (2008). Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans. Clinical Pharmacology & Therapeutics. 84(3). 332–339. 94 indexed citations
12.
Schelleman, Hedi, Olaf H. Klungel, J. C. M. Witteman, et al.. (2007). Pharmacogenetic interactions of three candidate gene polymorphisms with ACE‐inhibitors or β‐blockers and the risk of atherosclerosis. British Journal of Clinical Pharmacology. 64(1). 57–66. 12 indexed citations
13.
Schelleman, Hedi, Olaf H. Klungel, Jacqueline C.M. Witteman, et al.. (2007). Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or β-blockers. European Journal of Human Genetics. 15(4). 478–484. 41 indexed citations
14.
Schelleman, Hedi, Olaf H. Klungel, Jacqueline C.M. Witteman, et al.. (2006). Diuretic–gene interaction and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal. 7(5). 346–352. 12 indexed citations
15.
Schelleman, Hedi, Olaf H. Klungel, Jacqueline C.M. Witteman, et al.. (2006). The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. European Journal of Human Genetics. 14(7). 860–866. 19 indexed citations
16.
Schelleman, Hedi, Olaf H. Klungel, Cornelia M. van Duijn, et al.. (2005). Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors. British Journal of Clinical Pharmacology. 59(4). 483–485. 8 indexed citations
17.
Schelleman, Hedi, Bruno H. Stricker, W. M. Monique Verschuren, et al.. (2005). Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. The Pharmacogenomics Journal. 6(1). 22–26. 33 indexed citations
18.
Bakker, Steven C., et al.. (2004). DAT1, DRD4, and DRD5 polymorphisms are not associated with ADHD in Dutch families. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 132B(1). 50–52. 47 indexed citations
19.
Schelleman, Hedi, Bruno H. Stricker, Anthonius de Boer, et al.. (2004). Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy. Drugs. 64(16). 1801–1816. 35 indexed citations
20.
Schelleman, Hedi, et al.. (2004). Prevalence and determinants of undertreatment of hypertension in the Netherlands. Journal of Human Hypertension. 18(5). 317–324. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen D. Wise Breakdown of academic impact, for papers by Menger Chung Breakdown of academic impact, for papers by Wayne T. Nicholson Breakdown of academic impact, for papers by Marine L. Andersson Breakdown of academic impact, for papers by Rebecca N Gray Breakdown of academic impact, for papers by Д. А. Сычев Breakdown of academic impact, for papers by LE Ramsay Breakdown of academic impact, for papers by A Breckenridge Breakdown of academic impact, for papers by Lindon Wing Breakdown of academic impact, for papers by M. Kristensen
Rankless by CCL
2026